A Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for Single Dose Administration of TLC599 in Patients With Osteoarthritis (OA) of Knee
Phase of Trial: Phase II
Latest Information Update: 16 Jul 2017
At a glance
- Drugs Dexamethasone (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Taiwan Liposome Company
- 25 Apr 2017 Status changed from not yet recruiting to recruiting.
- 03 Jan 2017 According to a Taiwan Liposome Company media release, data will be un-blinded once the 24 week follow-up period is up for all 72 patients.
- 03 Jan 2017 According to a Taiwan Liposome Company media release, company announced the approval of an investigational new drug (IND) application for this study of TLC599.